Mutational analysis has also been advocated in the adjuvant setting [6–8]: a recent trial on the relationship between tumor genotype and benefits of adjuvant imatinib reported that GIST with a KIT exon 11-deletion respond positively to treatment, with a significantly longer recurrence-free survival compared with placebo. The gene discussed is KIT; the disease is neoplasm.